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Evaluating the bromodomain 
protein BRD1 as a therapeutic 
target in rheumatoid arthritis
Kerstin Klein1, Masaru Kato1, Mojca Frank-Bertoncelj1, Christoph Kolling  2, Adrian Ciurea1, 
Steffen Gay1 & Caroline Ospelt  1
Targeting epigenetic reader proteins by small molecule inhibitors represents a new therapeutic concept 
in autoimmune diseases such as rheumatoid arthritis (RA). Although inhibitors targeting bromodomain 
protein 1 (BRD1) are in development, the function of BRD1 has hardly been studied. We investigated 
the therapeutic potential of BRD1 inhibition in joint-resident cells in RA, synovial fibroblasts (SF) 
and macrophages. The proliferation of SF was decreased upon BRD1 silencing, accompanied by the 
downregulation of genes involved in cell cycle regulation. Silencing of BRD1 in SF decreased the basal 
expression of MMP1 but increased TNF-α- and LPS-induced levels of MMP3, IL6 and IL8. In monocyte-
derived macrophages (MDM), silencing of BRD1 decreased the LPS-induced expression of TNF-α, but 
did not significantly affect basal and the TNF-α- and LPS-induced expression of IL6 and IL8. Our data 
point to a cell type- and a stimulus-specific function of BRD1. Inhibiting BRD1 could have potential 
beneficial effects in RA via decreasing the proliferation of SF. Anti-inflammatory effects were limited 
and only observed in MDM.
Histone lysine acetylation, in combination with other post-translational modifications and DNA methylation 
determines the epigenetic code that regulates gene expression. Enzymes that read and erase histone acetylation 
marks are involved in regulating pathogenic pathways in rheumatoid arthritis (RA), including inflammation1. 
Bromodomain proteins (BRD) are epigenetic readers of acetylated histones. Targeting BRDs by small-molecule 
inhibitors has emerged as a new potential therapy in inflammation and arthritis2. Inhibitors against the family 
of bromodomain and extra-terminal (BET) proteins exhibit anti-inflammatory properties3 and show beneficial 
effects in RA synovial fibroblasts (RASF)4 and experimental arthritis5. First inhibitors targeting members of a dis-
tinct BRD family, the bromodomain and plant homeodomain finger-containing (BRPF) family, including BRPF1, 
BRD1 (BRPF2), and BRPF3 have recently been developed6,7, however, they have not been tested regarding their 
anti-inflammatory potential.
BRD1 has been identified as a subunit of the MOZ/MORF histone acetyltransferase (HAT) complex8. BRD1 
has been functionally linked to the acetylation of histone 3 lysine 14 (H3K14ac)9, a histone mark that co-occurs 
together with H3K9ac marks at active promoters. Furthermore, H3K14ac marks prime inactive genes for 
stimuli-dependent activation in mouse embryonic stem cells10. In anticitrullinated peptide antibody-positive RA 
patients, an intronic single nucleotide polymorphism (SNP; rs138845) in BRD1 was associated with the progres-
sion of joint destruction in stage I of a genome-wide association study11, providing a potential link between RA 
and BRD1. In this work, we evaluated the function of BRD1 in joint resident cells, specifically synovial fibroblasts 
(SF) and macrophages, and explored the potential of BRD1 inhibition as a treatment strategy in RA.
Results
Expression of BRD1 in the synovium. BRD1 was comparably expressed in synovial tissues of OA and 
RA patients (Figs 1a,b and S1), with some heterogeneity between patients. These differences were not due to a 
different joint of origin12 of these tissues (Supplementary Fig. S1). There was no difference in staining intensities 
of BRD1 between lining and sublining layers of synovial tissues. BRD1 was present in both SF and macrophages 
(Fig. 1c) as detected by double staining of synovial tissues with antibodies against BRD1 and prolyl 4-hydroxylase 
beta, a marker for fibroblasts, or CD68, a marker for macrophages. Immunofluorescence microscopy affirmed 
1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, 
Switzerland. 2Schulthess Clinic, Zurich, Switzerland. Correspondence and requests for materials should be addressed 
to K.K. (email: kerstin.klein@usz.ch)
Received: 2 January 2018
Accepted: 5 July 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCiEntifiC REpoRts |  (2018) 8:11125  | DOI:10.1038/s41598-018-29127-w
the nuclear expression of BRD1 in cultured RASF (Fig. 1d). There was no difference in the protein expression of 
BRD1 in RASF and OASF (Fig. 1e,f), which is in concordance with the results of the tissue staining.
Silencing of BRD1 reduces proliferation in RASF. To study its function, we silenced BRD1 in SF in 
presence and absence of TNF-α and LPS. The pro-inflammatory stimuli TNF-α and LPS increased the expres-
sion of BRD1 mRNA (Fig. 2a). The expression of BRD1 was significantly reduced in SF transfected with BRD1 
siRNA compared to scrambled transfected SF in unstimulated and stimulated conditions. Silencing of BRD1 was 
confirmed on the protein level (Fig. 2b,c).
In HeLa cells, p21, a potent inhibitor of cell cycle dependent kinases, has been described as a BRD1 target13. 
In SF, silencing of BRD1 reduced the basal and TNF-α-induced mRNA expression of cyclin dependent kinase 
(CDK1), cyclin A (CCNA2) and cyclin B1 (CCNB1). The mRNA expression of p21 was not affected by BRD1 
silencing (Fig. 2d). To test whether the differences in the gene expression of these cell cycle regulators translate 
into altered proliferation, we analysed the effect of BRD1 silencing on proliferation of RASF in presence and 
absence of TNF-α. Silencing of BRD1 decreased the proliferation of RASF, both in presence and absence of 
TNF-α (Fig. 2e,f). This effect was present during the entire time of the experiment (0–146 hours) (Fig. 2e), as 
well as during the exponential phase of the proliferation curve (40–80 hours) (Fig. 2f). TNF-α increased the pro-
liferation of scrambled- and siBRD1-transfected cells. However, whereas in scrambled-transfected cells, TNF-α 
increased proliferation throughout the time of the experiment (0–146 hours), TNF-α increased proliferation 
only at later stages (70–146 hours) in BRD1 silenced RASF (Fig. 2e). To exclude that the effects on proliferation 
Figure 1. Synovial expression of BRD1. (a) Synovial tissues from OA and RA patients were stained with 
anti-BRD1 (brown) antibodies or isotype control (box). Nuclei were counter stained with hemalaun (blue). 
Representative pictures are shown from one RA patient (elbow) and one OA patient (shoulder); please see also 
Supplementary Fig. S1. (b) Staining intensities (SI) in OA (n = 15) and RA (n = 18) tissues were scored (1: little 
staining – 4: strong staining) and difference was analysed by t-test. (c) Synovial tissues were double stained with 
anti-BRD1 (brown) antibodies and anti-CD68 antibodies (blue) or antibodies against prolyl 4-hydroxylase beta, 
a fibroblast marker (FB, green). Representative pictures are shown from one RA patient (elbow). (d) Cultured 
RASF were stained with anti-BRD1 (green) antibodies or isotype control (box). Actin fibres were stained 
with phalloidin (red). (e) The protein expression of BRD1 in OASF (n = 7) and RASF (n = 7) was analysed 
by Western blotting. The expression of α-tubulin was used as an endogenous control. Full-length blots are 
presented in Supplementary Fig. S2. (f) Band intensities of Western blots were analysed by densitometry.
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resulted from an altered adherence of the cells to plastic after silencing of BRD1, we analysed the cell index within 
the first 90 minutes of the experiment. Silencing of BRD1 in presence and absence of TNF-α had no effect on the 
ability of RASF to adhere to plastic (Fig. 2g). Furthermore, apoptosis was not changed between scrambled- and 
BRD1-transfected RASF (Supplementary Fig. S4), excluding that differences in cell death are the cause of the 
observed changes in proliferation.
Cell-type specific regulation of gene expression upon silencing of BRD1. Since the inhibition of 
BET proteins reduced the expression of inflammatory cytokines and MMPs in both RASF4 and macrophages3, we 
analysed changes in gene expression in RASF, OASF and monocyte-derived macrophages (MDM) after silenc-
ing of BRD1. Silencing of BRD1 in RASF and OASF reduced the basal MMP1 mRNA expression and secretion 
(Fig. 3a,c) but had no effect on the TNF-α- or LPS-induced expression and secretion of MMP1. In contrast, the 
TNF-α- and LPS-induced expression and secretion of MMP3, IL6 and IL8 were increased by BRD1 silencing 
(Fig. 3b,c), without affecting the basal mRNA expression and protein secretion (Fig. 3a,c). These data point to a 
rather pro-inflammatory effect of BRD1 silencing in SF.
Silencing of BRD1 in MDM was confirmed by Real-time PCR (Fig. 3a) and Western blotting (Fig. 3b,c). LPS 
increased the mRNA expression of BRD1. However, in MDM transfected with BRD1 siRNA, levels were signif-
icantly decreased compared to scrambled transfected SF in all conditions (Fig. 4a). Silencing of BRD1 in MDM 
from healthy donors and RA patients exhibited mild anti-inflammatory effects. The basal expression of IL8 mRNA 
was slightly but not significantly reduced by silencing of BRD1 in MDM (Fig. 4d, n = 8, p = 0.0562). Furthermore, 
silencing of BRD1 reduced the LPS-induced expression of TNF-α mRNA (Fig. 4e) but not the TNF-α-induced 
expression of TNF-α mRNA. This points to a stimulus-dependent regulation of TNF-α in BRD1-silenced MDM. 
The TNF-α-and LPS-induced expression of IL6 and IL8 were not affected by BRD1 silencing in MDM (Fig. 4e).
Figure 2. Silencing of BRD1 reduces the proliferation of RASF. RASF and OASF were transfected with siRNAs 
targeting BRD1 or scrambled siRNAs. 24 h after transfection, cells were stimulated with TNF-α (10 ng/ml) or 
LPS (100 ng/ml). (a) The mRNA and (b) protein expression of BRD1 was analysed by quantitative Real-time 
PCR and by Western blotting. Full-length blots are presented in Supplementary Fig. S3. (c) Band intensities 
of Western blots were analysed by densitometry. (d) The mRNA expression of genes involved in cell cycle 
regulation was analysed in transfected RASF (black; n = 6) and OASF (grey; n = 5) by quantitative Real-time 
PCR. Differences between groups were analysed by t-test. The proliferation of transfected RASF (n = 6) was 
analysed in quadruplicates using the Real-time cell-based adhesion and proliferation assays (xCELLigence 
System) (e) during the entire experiment (0–146 hours) and (f) during the exponential phase of the curve (40–
80 hours). Differences in proliferation were analysed by one-way ANOVA (e) or by t-test (f). (g) The adhesion to 
plastic was monitored within the first 90 minutes after cell seeding. *p < 0.05, **p < 0.01, ***p < 0.001.
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Discussion
Inhibitors targeting the bromodomain of BRD1 (BRPF2) have recently been developed6,7 but there is a lack of 
knowledge on the functional role of BRD1 in adult tissues. In our study, we assessed the role of BRD1 in joint 
resident cells, SF and macrophages which both contribute to hyperplasia of the synovium and promotion of 
inflammation found in RA14. By conducting silencing experiments in SF and MDM, we analysed here for the first 
time the functional role of BRD1 regarding its potential role in inflammation, matrix degradation and prolifera-
tion. Our silencing experiments suggest a role of BRD1 in the regulation of proliferation of SF. This is in line with 
silencing of BRD1 in HeLa cells that increased expression of p21, a negative regulator of cell cycle progression13. 
In SF, silencing of BRD1 did not affect the expression of p21 but reduced the expression of CDK1, cyclin A2 and 
cyclin B2. This suggests that BRD1 regulates the transition of G1/S as well as G2/M phases of the cell cycle in SF. 
Figure 3. BRD1 regulates the MMP and cytokine production in RASF and OASF. RASF and OASF were 
transfected with siRNAs targeting BRD1 or scrambled siRNAs. 24 h after transfection, cells were stimulated 
with TNF-α (10 ng/µl) or LPS (100 ng/µl). The mRNA expression of MMP1, MMP3, IL6, IL8 after silencing in 
(a,b) RASF (black; n = 11) and OASF (grey; n = 5) was analysed by quantitative Real-time PCR. (c) Effects of 
BRD1 silencing on MMP1, MMP3, IL6 and IL8 protein secretion in RASF (n = 8–9) was analysed by ELISA. 
Differences between groups were analysed by t-test. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4. BRD1 regulates the MMP and cytokine production in MDM. MDM were transfected with siRNAs 
targeting BRD1 or scrambled siRNAs. 24 h after transfection, cells were stimulated with TNF-α (10 ng/µl) or 
LPS (100 ng/µl). (a) The mRNA and (b) protein expression of BRD1 was analysed by quantitative Real-time 
PCR and by Western blotting. Full-length blots are presented in Supplementary Fig. S5. (c) Band intensities of 
Western blots were analysed by densitometry. (d,e) The mRNA expression of TNFα, IL6, and IL8 after BRD1 
silencing in MDM from healthy donors (black; n = 6) and RA patients (grey; n = 2) was analysed by quantitative 
Real-time PCR. Differences between groups were analysed by t-test. (D) *p < 0.05, **p < 0.01, ***p < 0.001.
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In a panel of cancer cell lines, both BRD1-specific and BRPF pan-inhibitors exhibited a modest or no effects on 
proliferation6,7. Collectively, these differences might reflect cell type-specific effects or point to functional differ-
ences between silencing of a multi-domain protein compared to blocking its bromodomain only.
Beside the anti-proliferative effect in SF, we showed that BRD1 regulates cytokine and MMP gene expression in a 
cell type- and stimulus-specific manner. Effects of BRD1 inhibition on other arthritis-relevant cell types in addition 
to SF and MDM are likely since BRD1 is expressed also in T- and B-cells15,16. BRD1 plays an important role in T cell 
development and is indispensable for the activation of the CD8 gene during early thymocyte development15. In SF, 
silencing of BRD1 exhibited rather pro-inflammatory and pro-destructive functions in presence of inflammatory 
stimuli. We did not observe any differences in SF from RA and OA patients, in accordance with the comparable 
expression of BRD1 in RA and OA tissues. Furthermore, there were no differences after BRD1 silencing in SF derived 
from different joint origin with respect to measured gene products. In MDM the LPS- induced expression of TNF-α 
was decreased by BRD1 silencing. This anti-inflammatory effect in MDM was stimulus-specific, since TNF-α did 
not affect the expression of TNF-α mRNA upon BRD1 silencing. This is in line with previous studies that showed a 
stimulus-specific expression of TNF-α in different cell types in vitro and in vivo17–19. A cell-type specific regulation of 
IL6 in SF and CD14+ monocytes has been described also previously by Noss et al. who identified a single nucleotide 
polymorphism in the IL6 promoter that affected only the expression of IL6 in SF from RA and OA patients but not in 
monocytes20. We have recently showed a cell-type specific regulation of a larger panel of cytokines, chemokines and 
MMPs in SF and MDM upon repeated stimulation with LPS. This coincided with a different epigenetic architecture 
at the promoters of these genes in unstimulated SF and monocytes, leading to a cell-type specific regulation of these 
genes after stimulation with LPS21. BRD1 is associated with a HAT complex adding H3K14ac marks to active gene 
promoters9. H3K14ac marks are rapidly induced in promoter regions of IL6, IL8 and TNF-α by inflammatory stimuli 
in different cell types22,23. In THP-1 monocytes, H3K14ac marks preceded the recruitment of the p65 in the TNF-α 
promoter upon stimulation with S100b proteins22, suggesting a role of H3K14ac in the activation of the TNF-α pro-
moter. Unfortunately, there are no public data sets on H3K14ac marks available that would enable a comparison of 
this histone modification in inflammatory gene promoters in macrophages and SF or other fibroblasts.
In IL-4-stimulated macrophages, pan-BRPF inhibitors modulated the secretion of CCL-22. However, depending 
on the concentration of these inhibitors, both a decreased and an increased secretion of CCL-22 were observed7, 
making the interpretation of the results difficult. In addition, BRPF inhibitors were mentioned to impair the 
RANKL-induced differentiation of monocytes into bone resorbing osteoclasts7. These results, together with the 
reported BRD1 SNP (rs138845) and our findings suggest a potential role of BRD1 in the pathogenesis of arthritis. 
In contrast to BET protein inhibition, that has a broad range of anti-inflammatory and anti-proliferative effects in 
diverse cell types in vitro and in vivo24, BRD1 inhibition rather exhibits a cell type and stimulus-specific functions 
with only limited anti-inflammatory effects with respects to the studied gene products and cell types. Therefore, 
BRPF inhibitors should be tested in many different cell types and under different stimulatory conditions.
Methods
Patient samples and cell preparation. Synovial fibroblasts of RA and osteoarthritis (OA) patients and 
monocyte-derived marcophages (MDM) from healthy volunteers and RA patients were cultured as described21. 
All patients fulfilled the criteria for the classification of RA25 and OA26. The characteristics of patients undergoing 
joint replacement surgery is shown in Table 1. The studies were approved by the local ethic committee of the 
University Hospital Zurich, Switzerland. Informed consent was obtained from all patients and healthy volunteers. 
All experiments have been performed in accordance with the institutional guidelines.
Transfection experiments. 3.5 × 105 RASF or OASF and 6.5 × 105 MDM were transfected with a pool of two 
different siRNAs (2 × 0.75 μM) targeting BRD1 or scrambled siRNAs (Qiagen) as a control using the Amaxa Basic 
Nucleofector Kit for Primary Mammalian Fibroblasts or the Human macrophage nucelofector kit (Lonza). 24 h after 
transfection cells were stimulated with TNF-α (10 ng/ml) or LPS (100 ng/ml) as indicated for another 24 h.
Immunohistochemistry and Immunofluorescence. After deparaffinization, tissue sections of RA and OA 
patients were pre-treated with citrate buffer (10 mM sodium citrate, pH 6.0). Endogenous peroxidase activity was 
disrupted with 3% H2O2. Slides were permeabilized with 0.1% Triton in PBS. Nonspecific protein binding was blocked 
with 5% goat serum in antibody diluent (Dako). Polyclonal rabbit anti-BRD1 antibodies (abcam) and rabbit IgG1 were 
applied over night at 4 °C. Slides were washed in PBS-T (0.05% Tween 20 in PBS) and incubated with biotinylated goat 
anti-rabbit antibodies (Jackson ImmunoResearch). The signal was amplified with ABC reagent for peroxidase (Vector 
Laboratories, Burlingame, CA) and detected with 3,3′-diaminobenzidine (Vector Laboratories). Staining intensities 
(SI) of tissues were scored (1: little staining – 4: strong staining) independently by two researches. For double staining, 
slides were stained with either the fibroblast marker prolyl 4-hydroxylase beta (Acris), CD68 (DakoCytomation) or 
IgG the day after staining for BRD1. Slides were washed in PBS-T and incubated with biotinylated goat anti-mouse 
antibodies. The signal was amplified with ABC reagent and detected with either Vector blue (Vector laboratories) or 
HistoGreen (Linaris). For immunofluorescence stainings, RASF were cultured in chamber slides (Lab-Tek, Nunc), 
fixed with 4% paraformaldehyde and permeabilized with tris-buffered saline (TBS) containing 0.1% Triton X-100. 
Nonspecific binding was blocked with 5% goat serum. Slides were incubated with polyclonal rabbit anti-BRD1 anti-
bodies and rabbit IgG1 overnight at 4 °C. After washing, slides were incubated with FITC- conjugated secondary anti-
bodies (Thermo Scientific). Actin filaments were stained with phalloidin (Sigma-Aldrich). Slides were covered with 
fluorescent mounting medium (Dako) and analysed with a fluorescence microscope (Axio Imager).
Quantitative Real-time polymerase chain reaction (RT-PCR). Total RNA was isolated from cells using 
the ReliaPrep RNA Cell Miniprep System (Promega) including on-column DNaseI digest and reversed transcribed. 
Real-time PCR was performed using SYBR green (Life Technologies). Primer sequences are available on request. 
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Constitutively expressed human ribosomal protein large P0 (RPLPO) was measured for internal standard sample 
normalization. Relative mRNA expression was calculated by the comparative threshold cycle method (ΔΔCt).
Western blotting. Western blotting was performed as described in detail previously4. Membranes were 
probed with antibodies against BRD1 (abcam) or α-tubulin (abcam). As secondary antibodies, horseradish 
peroxidase-conjugated goat anti-rabbit or goat anti-mouse antibodies (Jackson ImmunoResearch) were used. 
Signals were detected using the ECL Western blotting detection reagents (GE Healthcare) and the Alpha Imager 
Software system (Alpha Innotech).
ELISA. MMP1, MMP3, IL6 and IL8 were measured using the human total MMP-1 ELISA kit, the human total 
MMP-3 ELISA kit, the human IL-6 ELISA Set, and the human IL-8 ELISA Set (BD Biosciences), respectively in 
cell culture supernatants.
Adhesion and proliferation assay. Proliferation and adhesion (towards plastic) of transfected RASF 
was analysed using an impedance-based system for Real-time proliferation and adhesion assays (xCELLigence 
System, Bucher Biotec AG). Cells were seeded into E-plates 24 h after transfection at a densitiy of 2500 cells/well. 
TNF-α (10 ng/ml) was added simultaneously during seeding. Each condition was analysed in quadruplicates. 
Impedance changes were recorded every 15 minutes (0–24 hours) and every 30 minutes (24–146 hours). Adhesion 
was analysed over the first 90 minutes of the experiment. Proliferation was analysed during the exponential phase 
of the slopes (40–80 hours) and over the entire period of the experiment (0–146 hours).
Analysis of cell death. SF were incubated with FITC Annexin V (BD Biosciences) and propidium iodide 
(Sigma-Aldrich) for 15 minutes at room temperature in the dark, as recommended by manufacturer’s protocol 
(BD Biosciences), and analysed by flow cytometry (FACSCalibur, BD Biosciences).
Statistical analysis. Statistical analysis on data sets was carried out by using the GraphPad Prism program 
(GraphPad Software, San Diego, CA). N numbers in all experiments represent biological samples from different 
patients. Differences between experimental groups were analyzed by paired t-test or Wilcoxon signed rank test for anal-
ysis of basal expression. Differences in proliferation (0–146 h) were analysed by one-way ANOVA. Data are reported 
as means ± standard deviations. P values < 0.05 were considered significant. Raw data files are available on request.
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